X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Shattuck will lead discovery research of certain prespecified compounds directed toward a pair of targets selected by Ono from Shattuck’s pipeline of bifunctional fusion proteins in autoimmune and inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: $227.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 13, 2024
Details:
The gross proceeds will be allocated towards the clinical development of the company's lead product, SL-172154, currently undergoing Phase I trial studies for the treatment of Squamous Cell Carcinoma of the Head and Neck, as well as Cutaneous Squamous Cell Carcinoma.
Lead Product(s): SL-172154
Therapeutic Area: Oncology Product Name: SL-172154
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Evercore ISI
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 21, 2023
Details:
SL-172154 (SIRPα-Fc-CD40L) is an investigational ARC fusion protein designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune response in patients with advanced cancer.
Lead Product(s): SL-172154,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SL-172154
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
GADLEN compounds are comprised of two distinct fusion protein chains, with an engineered Fc linker domain that facilitates heterodimerization between the two chains.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Preclinical data for SL-9258 (TIGIT-Fc-LIGHT), a bispecific fusion protein from its ARC platform, demonstrating that SL-9258 simultaneously provides checkpoint blockade to all tumor-expressed PVR ligands and broadens immune costimulation by the TNF ligand known as LIGHT.
Lead Product(s): SL-9258,Undiscloed
Therapeutic Area: Oncology Product Name: SL-9258
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
The first poster will highlight preclinical data from GADLEN™ platform, while the second will highlight preclinical data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform, demonstrating its ability to broaden the activity of checkpoint inhibitors.
Lead Product(s): SL-9258
Therapeutic Area: Oncology Product Name: SL-9258
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The phase 1 trial is an open label, multi-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, anti-tumor activity, and pharmacodynamic effects of SL-172154 administered intravenously in patients with platinum resistant ovarian cancer.
Lead Product(s): SL-172154
Therapeutic Area: Oncology Product Name: SL-172154
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2021
Details:
Preclinically, SL-9258 (TIGIT-Fc-LIGHT) retained activity in a PD1 resistance model and outperformed dual checkpoint blockade with anti-PD1 and anti-TIGIT.
Lead Product(s): SL-9258
Therapeutic Area: Oncology Product Name: SL-9258
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The study will evaluate the safety, tolerability, pharmacokinetics, anti-tumor, and pharmacodynamic effects of SL-172154. In addition, Shattuck plans to evaluate SL-172154 in combination with other therapeutic agents in specific cancers.
Lead Product(s): SL-172154
Therapeutic Area: Oncology Product Name: SL-172154
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
